Tigo Energy Solar Rapid Shutdown Selected by Constructora San Jose for 142MWp Solar System
6.6.2024 16:00:00 EEST | Business Wire | Press release
Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced that premier Engineering, Procurement, and Construction (EPC) firm, Constructora San Jose, S.A., has selected Tigo as the rapid shutdown technology provider for a 142MWp solar installation for an industrial ground mount in Spain. Reliable rapid shutdown functionality is essential to providing fire safety for system owners and eliminates the risk of encountering high-voltage DC electricity for operations and maintenance, as well as emergency personnel in case of contact with the system during service intervals or in emergency situations.
The system, which will produce clean energy to help serve the demand from local industry and feed excess energy back to the public grid, will include more than 107,000 Tigo TS4-A-2F MLPE devices and produce in excess of 142MWp. The project also includes more than 550 Tigo RSS Transmitters with Pure Signal technology, which eliminates disturbances in PLC signals from adjacent cable runs and improves the effectiveness of system communications functions in large and complex systems.
“With the responsibility that comes with a system of this size, the reliability and quality of Tigo was the ideal option for rapid shutdown safety,” said Diego Navarro, purchasing manager at Constructora San Jose, S.A. “In contrast to roof-mounted solar systems, the risk of contact with a ground-mounted system is somewhat higher, which is why reliable rapid shutdown is essential. With a project that will become part of the critical energy infrastructure in the region, it is important to get everything right, and the Tigo Green Glove program has provided outstanding support service throughout the process.”
The TS4-A-2F is a reliable and cost-effective two-module rapid shutdown solution that meets the latest module-level shutdown requirements, including NEC 2017/2020. The TS4-A-2F is both IEC and UL-certified for global acceptance and UL-PVRSS-certified for connectivity with the largest network of inverters. Constructora San Jose selected the TS4-A-2F to support the 670W modules used in the project, which will be under construction during the second half of 2024, with commissioning expected in the first half of 2025.
“It is an honor to have won the trust of Constructora San Jose, S.A. for this project, and we look forward to delivering on Total Quality Solar as the project moves through installation and into the operations phase,” said Mirko Bindi, Senior VP Sales EMEA & MD Europe at Tigo Energy Inc. “We design our technology to be both reliable and offer design flexibility, and this system once again shows that as system complexity and size increases, Tigo provides a great solution. The Tigo Green Glove support team will be there for the Constructora San Jose team throughout the project, with a focus on end-to-end installation quality and long-term system safety.”
The Tigo TS4 platform maximizes the benefit of PV systems for installers on all continents. With a system size range from 2kW to more than 100MW and installation in less than ten seconds per module, Tigo has a trusted and reliable product portfolio deployed around the world, from rapid shutdown to module-level monitoring and advanced energy optimization.
For more information about the Tigo TS4-A-2F MLPE device, please visit the product website here. For more information about the Tigo Green Glove program for C&I solar installers, please visit the program website here.
About Tigo Energy
Founded in 2007, Tigo is a worldwide leader in the development and manufacture of smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Tigo combines its Flex MLPE (Module Level Power Electronics) and solar optimizer technology with intelligent, cloud-based software capabilities for advanced energy monitoring and control. Tigo MLPE products maximize performance, enable real-time energy monitoring, and provide code-required rapid shutdown at the module level. The company also develops and manufactures products such as inverters and battery storage systems for the residential solar-plus-storage market. For more information, please visit www.tigoenergy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606641822/en/
Contact information
Technica Communications
Cait Caviness
Email: tigoenergy@technica.inc
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom